WASHINGTON–(BUSINESS WIRE)–The Melanoma Research Alliance (MRA) has released the following statements from MRA Scientific Director Marc Hurlbert, PhD, and President and CEO Michael Kaplan regarding the Food & Drug Administration’s approval of relatlimab plus nivolumab:
Marc Hurlbert, PhD, Scientific Director of ARM: “It’s exciting to see a new, first-in-class immunotherapy against the LAG-3 checkpoint, a real obstacle preventing the immune system from attacking cancers, be approved for the treatment of advanced melanoma. The potential therapeutic use of LAG-3 therapeutic agents in melanoma was identified by Drew Pardoll, MD, PhD, whose work was supported in part by a 2009 MRA Team Scientist Award. Today’s approval today also marks the 15and melanoma treatment approved over the past decade – truly amazing advancements for researchers and patients.
Michael Kaplan, President and CEO of MRA: “Today’s approval is an important milestone for melanoma patients. It is particularly gratifying to see a therapeutic LAG-3 – discovered in part through WARC-funded work – now available to patients at the clinic.
About the Melanoma Research Alliance (MRA)
The Melanoma Research Alliance exists to expedite treatment options and find a cure for melanoma. As the largest nonprofit funder of melanoma research, it has committed more than $131 million and leveraged an additional $415 million in follow-on and collaborative funding for its mission. Thanks to its support, MRA has championed revolutions in immunotherapy, targeted therapies, new combinations and diagnostics. Thanks to the continued support of its founders, 100% of donations to MRA go directly to its melanoma research program. MRA’s ability to fund large-scale melanoma research is amplified through unique collaborations and partnerships with individuals, private foundations and corporations. Visit http://www.CureMelanoma.org for more information.